EUR 4.9
(1.07%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 13.64 Million EUR | -19.69% |
2022 | 19.13 Million EUR | 38.2% |
2021 | 13.84 Million EUR | 1012.1% |
2020 | 1.24 Million EUR | -92.69% |
2019 | 17.02 Million EUR | 14.31% |
2018 | 14.89 Million EUR | 18.27% |
2017 | 12.59 Million EUR | -9.83% |
2016 | 13.96 Million EUR | 82.7% |
2015 | 7.64 Million EUR | 76.64% |
2014 | 4.32 Million EUR | 87.28% |
2013 | 2.31 Million EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 Q2 | 7.8 Million EUR | 4.82% |
2023 FY | 15.36 Million EUR | -19.69% |
2023 Q4 | 7.55 Million EUR | -3.18% |
2022 Q4 | 7.44 Million EUR | -36.27% |
2022 FY | 19.13 Million EUR | 38.2% |
2022 Q2 | 11.68 Million EUR | 195.43% |
2021 FY | 13.84 Million EUR | 1012.1% |
2021 Q4 | 3.95 Million EUR | 6492.64% |
2021 Q2 | 60 Thousand EUR | -50.39% |
2020 Q2 | 1.12 Million EUR | -86.55% |
2020 FY | 1.24 Million EUR | -92.69% |
2020 Q4 | 120.94 Thousand EUR | -89.24% |
2019 Q4 | 8.35 Million EUR | -3.57% |
2019 FY | 17.02 Million EUR | 14.31% |
2019 Q2 | 8.66 Million EUR | -5.32% |
2018 Q4 | 9.15 Million EUR | 59.49% |
2018 FY | 14.89 Million EUR | 18.27% |
2018 Q2 | 5.74 Million EUR | 4.76% |
2017 Q2 | 7.11 Million EUR | 13.43% |
2017 Q4 | 5.47 Million EUR | -22.99% |
2017 FY | 12.59 Million EUR | -9.83% |
2016 Q2 | 7.69 Million EUR | 72.9% |
2016 FY | 13.96 Million EUR | 82.7% |
2016 Q4 | 6.27 Million EUR | -18.48% |
2015 Q2 | 3.19 Million EUR | 0.0% |
2015 Q4 | 4.45 Million EUR | 39.28% |
2015 FY | 7.64 Million EUR | 76.64% |
2014 FY | 4.32 Million EUR | 87.28% |
2013 FY | 2.31 Million EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Nicox S.A. | -11.5 Million EUR | 218.639% |
FERMENTALG | 12.34 Million EUR | -10.556% |
argenx SE | 1.34 Billion EUR | 98.984% |
BioSenic S.A. | 7.58 Million EUR | -79.968% |
Celyad Oncology SA | 8.49 Million EUR | -60.742% |
Hyloris Pharmaceuticals SA | 17.98 Million EUR | 24.129% |
Onward Medical N.V. | 20.64 Million EUR | 33.897% |
Oxurion NV | 12.21 Million EUR | -11.732% |
PHAXIAM Therapeutics S.A. | 24.98 Million EUR | 45.381% |
Financière de Tubize SA | 114.38 Thousand EUR | -11830.343% |
UCB SA | 2.94 Billion EUR | 99.536% |